Добірка наукової літератури з теми "TTF triple"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "TTF triple".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "TTF triple"
1
Dranitsaris, George, Debu Tripathy, Nancy L. Beegle, Traci L. Kalberer, John David Cox, and Claudio Faria. "Real-world analysis of eribulin in metastatic breast cancer (MBC): An assessment of time to treatment failure (TTF) in a community oncology setting." Journal of Clinical Oncology 31, no. 26_suppl (September 10, 2013): 174. http://dx.doi.org/10.1200/jco.2013.31.26_suppl.174.
Повний текст джерелаАнотація:
174 Background: There have been important advances in the treatment of patients with MBC. However, certain patient subgroups such as whose who are triple negative remain a therapeutic challenge. Eribulin is the newest cytotoxic to gain regulatory approval for MBC in the Unites States. In this analysis, the safety and efficacy of eribulin in TNBC patients and those with prior anthracycline exposure were assessed in an early cohort treated in a U.S. community oncology setting. Methods: Ninety patients treated in eight community oncology clinics across the U.S. were identified. Patients were followed from the first cycle of eribulin until disease progression, discontinuation due to toxicity, or death. Data collection included baseline patient and disease characteristics, prior and subsequent anticancer therapy, use of supportive care drugs, number and type of dose limiting toxicity, delivered dose intensity, duration of eribulin therapy and time to treatment failure (TTF). Results: Eribulin was administered after a median of three prior lines of chemotherapy (range 0 to 15). The drug was delivered as a single agent in 79 of 90 patients (88%) at the clinically approved dosage of 1.4 mg/m2on days 1 and 8 of a 21 day cycle. Patients received a median of 4 cycles (1 to 16) for an overall mean duration of 2.9 months (0 to 14.2 months). Approximately 17 of 90 patients (18.9%) were identified as triple negative and 57 of 90 (63.3%) had received prior anthracycline treatment. The median TTF (inter quartile range) was 4 mon (2.3 to 5.6) in all patients. There were no significant differences in TTF by triple negative status (HR=0.1.22, p = 0.49) and prior exposure to anthracyclines (HR=0.78, p = 0.15). In all patients, the most common dose limiting toxicities were neutropenia (32%), anemia (31%), neuropathy (21%) and febrile neutropenia (8.9%). These events led to the premature discontinuation of eribulin in 8 of 90 patients (8.9%). Conclusions: TTF with eribulin was comparable regardless of triple negative status and prior exposure to anthracyclines. These findings are consistent with results from previous clinical studies and warrant further real-world analyses in a larger population.
2
Dranitsaris, George, Stefan Glück, Claudio Faria, David Cox, and Hope S. Rugo. "A comparative effectiveness analysis of single-agent cytotoxics in triple-negative metastatic breast cancer patients." Journal of Clinical Oncology 32, no. 26_suppl (September 10, 2014): 157. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.157.
Повний текст джерелаАнотація:
157 Background: There has been considerable progress in treatments for MBC. However, the identification of optimal cytotoxic agents in patients with triple negative disease (negative for hormone receptors, ER/PR and HER-2) remains a therapeutic challenge. A comparative effectiveness analysis of four cytotoxic agents was conducted in patients with TN MBC. Methods: We retrospectively identified 225 patients treated with single agent eribulin (E=47), capecitabine (C=69), gemcitabine (G=56) or vinorelbine (V=53) in 19 community oncology clinics across the US. Data collection included baseline patient characteristics, performance status, duration of current therapy, growth factor use and all dose limiting toxicities. Time to treatment failure (TTF) was measured from the first cycle of chemotherapy until disease progression, discontinuation due to toxicity, or death. TTF was then estimated using the Kaplan-Meier method and Cox proportional hazard modeling adjusted for clustering on the practice site. To control for selection bias that is inherent in observational studies, a propensity score weighted TTF analysis was also conducted. Results: Patients were comparable with respect to age, performance status, duration of disease free survival, presence of comorbidities and hemoglobin level prior to the start of chemotherapy. However, the median lines of therapy for use of C, G, V and E were 2nd, 3rd, 3rd, and 4th, respectively. The median duration of treatment was approximately 2 months with C, G, and E compared to 1.6 months with V. Using eribulin as the reference and adjusting for line of therapy and associated prognostic factors, the propensity score weighted Cox regression analysis did not identify statistically significant differences in TTF: C vs. E: HR = 1.15 (0.75 to 1.76), G vs. E: HR = 0.62 (0.34 to 1.13), V vs. E: HR = 1.0 (0.60 to 1.37). Conclusions: In patients with TN-MBC treated in a community oncology setting, eribulin was utilized in later lines than other agents. However, eribulin demonstrated at least comparable drug activity even when used in more heavily pretreated patients. These findings warrant further analyses in a larger population with an evaluation of biologic heterogeneity.
3
Maher, Mohamed, Shady H. E. Abdel Abdel Aleem, Ahmed M. Ibrahim, and Adel El-Shahat. "Novel Mathematical Design of Triple-Tuned Filters for Harmonics Distortion Mitigation." Energies 16, no. 1 (December 21, 2022): 39. http://dx.doi.org/10.3390/en16010039.
Повний текст джерелаАнотація:
The design of AC filters must meet the criteria of harmonic distortion mitigation and reactive power support in various operating modes. The stringent reactive power-sharing requirements currently lead to sophisticated filter schemes with high component ratings. In this regard, triple-tuned filters (TTFs) have good potential in harmonic mitigation of a broad range of harmonics. In the literature, the TTF design has been presented using a parametric method, assuming that the TTF is equivalent to a three-arm single-tuned filter (TASTF). However, no direct methods of designing it or finding its optimal parameters have been provided. This paper presents novel mathematical designs of TTFs. Three different design methods are considered—the direct triple-tuned filter (DTTF) design method, as a TASTF, and a method based on the equivalence between the two design methods called the equivalence hypothesis method to design the triple-tuned filter (EHF). The parameters of the three proposed design methods are optimized based on the minimization of a proposed multi-objective function using a recent metaheuristic algorithm called artificial rabbits optimization (ARO) to mitigate harmonics, improve power quality, and minimize power losses in an exemplary system presented in IEEE STD-519. Further, the system’s performance has been compared to the system optimized by the ant lion optimizer (ALO) and whale optimization algorithm (WOA) to validate the effectiveness of the proposed design. Simulation results emphasized harmonics mitigation in the system, the system losses reduction, and power quality improvement with lower reactive power filter ratings than conventional single and double-tuned filters.
4
Ahn, Sejung, Yukyung Kim, Seungjae Beak, Shohei Ishimoto, Hideo Enozawa, Eigo Isomura, Masashi Hasegawa, Masahiko Iyoda, and Yungwoo Park. "Synthesis and electrical conductivity of perchlorate-doped TTF–diamide nanofibers with double and triple helix structures." Journal of Materials Chemistry 20, no. 48 (2010): 10817. http://dx.doi.org/10.1039/c0jm02628j.
Повний текст джерела
5
Schwingshackl, Andreas, Benjamin Lopez, Bin Teng, Charlean Luellen, Florian Lesage, John Belperio, Riccardo Olcese, and Christopher M. Waters. "Hyperoxia treatment of TREK-1/TREK-2/TRAAK-deficient mice is associated with a reduction in surfactant proteins." American Journal of Physiology-Lung Cellular and Molecular Physiology 313, no. 6 (December 1, 2017): L1030—L1046. http://dx.doi.org/10.1152/ajplung.00121.2017.
Повний текст джерелаАнотація:
We previously proposed a role for the two-pore domain potassium (K2P) channel TREK-1 in hyperoxia (HO)-induced lung injury. To determine whether redundancy among the three TREK isoforms (TREK-1, TREK-2, and TRAAK) could protect from HO-induced injury, we now examined the effect of deletion of all three TREK isoforms in a clinically relevant scenario of prolonged HO exposure and mechanical ventilation (MV). We exposed WT and TREK-1/TREK-2/TRAAK-deficient [triple knockout (KO)] mice to either room air, 72-h HO, MV [high and low tidal volume (TV)], or a combination of HO + MV and measured quasistatic lung compliance, bronchoalveolar lavage (BAL) protein concentration, histologic lung injury scores (LIS), cellular apoptosis, and cytokine levels. We determined surfactant gene and protein expression and attempted to prevent HO-induced lung injury by prophylactically administering an exogenous surfactant (Curosurf). HO treatment increased lung injury in triple KO but not WT mice, including an elevated LIS, BAL protein concentration, and markers of apoptosis, decreased lung compliance, and a more proinflammatory cytokine phenotype. MV alone had no effect on lung injury markers. Exposure to HO + MV (low TV) further decreased lung compliance in triple KO but not WT mice, and HO + MV (high TV) was lethal for triple KO mice. In triple KO mice, the HO-induced lung injury was associated with decreased surfactant protein (SP) A and SPC but not SPB and SPD expression. However, these changes could not be explained by alterations in the transcription factors nuclear factor-1 (NF-1), NKX2.1/thyroid transcription factor-1 (TTF-1) or c-jun, or lamellar body levels. Prophylactic Curosurf administration did not improve lung injury scores or compliance in triple KO mice.
6
Peng, Yan, Yasmeen M. Butt, Beiyun Chen, Xinmin Zhang, and Ping Tang. "Update on Immunohistochemical Analysis in Breast Lesions." Archives of Pathology & Laboratory Medicine 141, no. 8 (June 5, 2017): 1033–51. http://dx.doi.org/10.5858/arpa.2016-0482-ra.
Повний текст джерелаАнотація:
Context.— The utility of immunohistochemistry (IHC) in breast lesions needs to be updated with exceptions among these lesions. Biomarker studies with IHC in triple-negative breast carcinoma may help develop targeted therapies for this aggressive breast cancer. The distinction of metastatic lung adenocarcinoma to the breast and invasive breast carcinoma has significant prognostic and therapeutic implications. The determination can be challenging because both primary tumors can express estrogen receptor and/or HER2 by IHC, creating a diagnostic dilemma. Objectives.— To provide a practical update on the use of IHC markers in differential diagnoses in breast lesions, including benign, atypical, precancerous, and malignant tumors; to highlight recently published research findings on novel IHC markers in triple-negative breast carcinoma cases; and to reinforce the importance of IHC use as an ancillary tool in distinguishing metastatic lung adenocarcinoma to the breast from primary breast carcinoma using real case examples. Data Sources.— PubMed (US National Library of Medicine, Bethesda, Maryland) literature review and authors' research data and personal experiences were used in this review. Conclusions.— Immunohistochemistry has an important role in making differential diagnoses in breast lesions in morphologically equivocal settings; recognizing IHC expression status in the exceptions among these lesions will aid in the correct diagnosis of challenging breast cases. Studies suggest that androgen receptor, p16, p53, GATA3, and PELP1 may have potential diagnostic, prognostic, and predictive value in triple-negative breast carcinoma cases; these findings may provide insight and a greater understanding of the tumor biology in triple-negative breast carcinomas. In distinguishing metastatic estrogen receptor–positive or HER2+ lung adenocarcinoma to the breast from primary breast carcinoma, napsin A, TTF-1, and GATA3 comprise a useful IHC panel.
7
El-Maqsoud, Nehad M. R. Abd, Ehab Rifat Tawfiek, Ayman Abdelmeged, Mohamed Fathy Abdel Rahman, and Alaa A. E. Moustafa. "The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas." Tumor Biology 37, no. 3 (October 1, 2015): 3123–34. http://dx.doi.org/10.1007/s13277-015-3964-3.
Повний текст джерела
8
Spiegel, Jay, Caroline Jane McNamara, Andrea Arruda, Tony Panzarella, James A. Kennedy, Tracy L. Stockley, Mahadeo Sukhai, et al. "Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy." Blood 128, no. 22 (December 2, 2016): 4263. http://dx.doi.org/10.1182/blood.v128.22.4263.4263.
Повний текст джерелаАнотація:
Abstract Introduction: The advent of next generation sequencing (NGS) has brought intense interest to the complex genetic landscape of myeloproliferative neoplasms (MPN). However, data regarding clinical outcomes in the context of novel MPN therapies such as JAK inhibitors are scarce. Limited data indicate that high molecular risk signature (HMR, presence of at least one mutation in ASXL1, EZH2, IDH1/2, SRSF2) or multiple mutations may be associated with decreased spleen response and a shorter time to discontinuation of Ruxolitinib in myelofibrosis (Patel et al, Blood 2015). Methods: All myelofibrosis patients seen in the MPN program at Princess Margaret Hospital between November 2009 and May 2016 and treated with JAK1/2 inhibitor therapy were identified. NGS molecular profiling of 54 genes (39 hotspot region; 15 complete coding region coverage) was performed on peripheral blood or bone marrow samples using the TruSight Myeloid Sequencing Panel. Reporting was restricted to well-covered, exonic nonsynonymous, intronic splice site, and known pathogenic synonymous variants. Variants with global mean allele frequency >1% were identified using multiple population databases (1000 genomes, ESP, ExAC) and excluded. The primary endpoint was time from start of JAK1/2 inhibitor therapy to treatment failure (TTF) defined as treatment discontinuation, progression to accelerated phase or leukemic transformation, spleen progression or death. Secondary endpoints included best spleen, anemia and IWG response achieved by 48 weeks of treatment and overall survival. Response was assessed according to the 2013 revised IWG-MRT criteria. Transfusion dependency was assessed as any transfusion in 12 weeks prior to treatment or being identified as transfusion dependent in medical history. Results: Of 159 patients treated with JAK1/2 inhibitors at our institution, 102 met the inclusion criteria (see Table 1). Patients were excluded if; no sample was available for analysis (19), short use of JAK inhibitor prior to transplant (9), active clinical trial (5), in accelerated phase/acute leukemia (4) and others (20). First JAK inhibitor used was ruxolitinib in 77 patients and momelotinib in 25. At least one mutation was identified in every patient. Twenty (20%) patients had one mutation, 32 (31%) had 2 mutations and 50 (49%) patients had ≥ 3 mutations. Eighty (82%) patients had the JAK2V617F mutation, 15 (15%) had mutations in CALR, 4 (4%) had MPL mutations and one patient was triple negative. One patient had mutations in both CALR and JAK2 while another had mutations in MPL and CALR. Forty-eight (47%) patients had mutations consistent with HMR profile. Mutation profile is summarized in Table 2. With median follow-up of 2.5 years, 51 (50%) patients experienced treatment failure. On univariate analysis, TTF was associated with DIPSS, pre-treatment transfusion status and Hb <100 prior to initiating JAK inhibitor therapy. However, TTF was not associated with specific driver mutations, the number of mutations or HMR profile. Exploratory analysis of genes mutated in ≥5% of the population showed EZH2 (p=0.004) and CBL (p=0.005) mutated patients had shorter TTF. Multi-variable analysis employing anemia <100 and DIPSS with either of the number of mutations or HMR profile did not show any association with TTF. There was a trend towards TTF in patients with Hb<100 (HR 2.21, 95%CI: 0.99-4.95, p=0.05). Of 102 patients, 91 were evaluable for spleen response with 43 (47%) achieving a spleen response by 48 weeks of treatment. Twelve (23%) of the 53 patients evaluated met criteria for anemia response. Neither spleen nor anemia response was associated with the use of a particular JAK inhibitor. Of the 95 patients with at least 48-week follow-up, best response while on treatment was clinical improvement and spleen response in 29 (31%) and 19 (20%) patients respectively. Conclusions: In this study of myelofibrosis patients treated with JAK inhibitors, EZH2 and CBL mutated patients had shorter TTF. We did not find any association between TTF and number of mutations or other high risk mutations such as ASXL1/SRSF2. Anemia was the only significant independent predictor of shorter TTF. Our findings highlight the need for multicenter collaborative studies on a large number of patients and cautious use of mutation profiling results in routine clinical decision making with current treatment approaches. Spiegel and McNamara are co-primary authors. Disclosures Panzarella: Cellgene: Consultancy. Schimmer:Novartis: Honoraria. Schuh:Amgen: Membership on an entity's Board of Directors or advisory committees. Yee:Novartis Canada: Membership on an entity's Board of Directors or advisory committees, Research Funding. Kamel-Reid:BMS: Research Funding. Gupta:Novartis: Consultancy, Honoraria, Research Funding; Incyte Corporation: Consultancy, Research Funding.
9
Eisen, Tim, Yaroslav Shparyk, Robert Jones, Nicholas James MacLeod, Graham Temple, Helen Finnigan, Rolf Kaiser, Matus Studeny, Arsene Bienvenu Loembe, and Igor Bondarenko. "Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 4506. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4506.
Повний текст джерелаАнотація:
4506 Background: Sunitinib (S) is established as a standard first-line therapy for patients (pts) with advanced RCC. However, treatment can be limited by the occurrence of drug-related adverse events (AEs). This Phase II study assessed the efficacy and safety of nintedanib (N) – a potent, triple angiokinase inhibitor of VEGFR-1–3, PDGFR-α/β, and FGFR-1–3, as well as RET and Flt3 – vs S in previously untreated pts with RCC. Methods: Ninety-nine eligible pts (96 of whom were treated) with advanced, unresectable/recurrent clear cell RCC, an ECOG performance status of 0–1, and no prior systemic therapy were randomized 2:1 to receive N 200 mg twice daily (n=64; given in 4-week cycles) or S 50 mg once daily (n=32; 4 weeks on, 2 weeks off schedule). Treatment continued until disease progression or unacceptable drug-related AEs. Primary endpoints were progression-free survival at 9 months (PFS-9) and, in N-treated pts only, QTc interval change (baseline to day 15). Secondary endpoints included PFS, objective response rate (ORR; RECIST 1.1), overall survival (OS), time to progression (TTP), time to treatment failure (TTF), and AEs. Results: Baseline characteristics were balanced between the arms. PFS-9 was not statistically significantly different between N- and S-treated pts (43 vs 45%; p=0.85). There were also no statistically significant differences between N and S with regard to PFS (median: 8.44 vs 8.38 mo; hazard ratio: 1.16; 95% CI: 0.71–1.89; p=0.56), confirmed ORR (18.8 vs 31.3%; p=0.19), OS (median: 20.37 vs 21.22 mo; p=0.63), TTP (median: 8.48 vs 8.54 mo; p=0.52), and TTF (median: 8.41 vs 8.36 mo; p=0.46). Grade ≥3 AEs occurred in 47% of N-treated pts and 56% of S-treated pts. Common AEs (all grades; N vs S) included diarrhea (61 vs 50%), nausea (38 vs 34%), fatigue (both 25%), and vomiting (16 vs 22%). Dermatologic AEs (8 vs 47%) were less frequent with N than S. There was no increase from baseline in QTc >60 ms on days 1 or 15 in N-treated pts, and there was no relationship between N exposure and QT interval change. Conclusions: N demonstrated similar efficacy to S and had a manageable safety profile, including a lower incidence of dermatologic AEs vs S. In addition, N was not associated with QT prolongation. Clinical trial information: NCT01024920.
10
Sharma, Rajni, Grzegorz Gurda, Susan Geddes, Edward Gabrielson, Frederic Askin, and Qing Kay Li. "Validation of the Novel Triple Marker (Combination of TTF, Napsin-A and p40) in the Subclassification of Non-Small Cell Lung Carcinomas (NSCLC) Using Fine Needle Aspiration (FNA) Cytological Materials." Journal of the American Society of Cytopathology 3, no. 5 (September 2014): S83. http://dx.doi.org/10.1016/j.jasc.2014.09.195.
Повний текст джерелаДисертації з теми "TTF triple"
1
Martini, Lorenzo. "Local coherence of hearts in the derived category of a commutative ring." Doctoral thesis, Università degli studi di Trento, 2022. http://hdl.handle.net/11572/354322.
Повний текст джерелаАнотація:
Approximation theory is a fundamental tool in order to study the representation theory of a ring R. Roughly speaking, it consists in determining suitable additive or abelian subcategories of the whole module category Mod-R with nice enough functorial properties. For example, torsion theory is a well suited incarnation of approximation theory. Of course, such an idea has been generalised to the additive setting itself, so that both Mod-R and other interesting categories related with R may be linked functorially. By the seminal work of Beilinson, Bernstein and Deligne (1982), the derived category of the ring turns out to admit useful torsion theories, called t-structures: they are pairs of full subcategories of D(R) whose intersection, called the heart, is always an abelian category. The so-called standard t-structure of D(R) has as its heart the module category Mod-R itself. Since then a lot of results devoted to the module theoretic characterisation of the hearts have been achieved, providing evidence of the usefulness of the t-structures in the representation theory of R. In 2020, following a research line promoted by many other authors, Saorin and Stovicek proved that the heart of any compactly generated t-structure is always a locally finitely presented Grothendieck categories (actually, this is true for any t-structure in a triangulated category with coproducts). Essentially, this means that the hearts of D(R) come equipped with a finiteness condition miming that one valid in Mod-R. In the present thesis we tackle the problem of characterising when the hearts of certain compactly generated t-structures of a commutative ring are even locally coherent. In this commutative context, after the works of Neeman and Alonso, Jeremias and Saorin, compactly generated t-structures turned out to be very interesting over a noetherian ring, for they are in bijection with the Thomason filtrations of the prime spectrum. In other words, they are classified by geometric objects, moreover their constituent subcategories have a precise cohomological description. However, if the ascending chain condition lacks, such classification is somehow partial, though provided by Hrbek. The crucial point is that the constituents of the t-structures have a different description w.r.t. that available in the noetherian setting, yet if one copies the latter for an arbitrary ring still obtains a t-structure, but it is not clear whether it must be compactly generated. Consequently, pursuing the study of the local coherence of the hearts given by a Thomason filtration, we ended by considering two t-structures. Our technique in order to face the lack of the ascending chain condition relies on a further approximation of the hearts by means of suitable torsion theories. The main results of the thesis are the following: we prove that for the so-called weakly bounded below Thomason filtrations the two t-structures have the same heart (therefore it is always locally finitely presented), and we show that they coincide if and only they are both compactly generated. Moreover, we achieve a complete characterisation of the local coherence for the hearts of the Thomason filtrations of finite length.
2
Paquet, Joseph. "Potentialités anti-inflammatoires de l'inhibition génomique et transcriptionnelle du TNF-[alpha] par une approche de type oligonucléotidique." Thesis, Nancy 1, 2010. http://www.theses.fr/2010NAN10067/document.
Повний текст джерелаАнотація:
Le Tumor Necrosis Factor alpha (TNF-[alpha]) est une cytokine pro-inflammatoire qui occupe un rôle central dans la physiopathologie de nombreuses pathologies inflammatoires et particulièrement l'arthrite. La neutralisation de cette cytokine par l'utilisation d'anticorps anti-TNF-[alpha] a montré son efficacité dans la polyarthrite rhumatoïde et est aujourd'hui le traitement de référence pour la prise en charge de cette pathologie. Cependant, un tiers des patients traités par anticorps anti-TNF restent réfractaires ou ne répondent pas à ce traitement. Dans ce contexte, il apparait nécessaire de développer des approches nouvelles ou complémentaires pour renforcer l'arsenal thérapeutique actuellement disponible. L'utilisation d'oligonucléotides triple hélice (TFO) permet de moduler l'expression génique de manière spécifique par interaction avec la double hélice d'ADN. Dans cette étude, nous avons évalué les potentialités anti-inflammatoires d'un TFO anti-TNF-[alpha] in vitro sur les synoviocytes et chondrocytes articulaires et in vivo dans deux modèles d'arthrite expérimentale. Ce TFO interagit avec le promoteur du gène du TNF-[alpha], et son activité inhibitrice a été comparée à celle d'une approche par ARN interférence in vitro. Dans les modèles d'arthrite aigue et chronique, l'injection intra-articulaire préventive de TFO anti-TNF-[alpha] permet une amélioration significative des symptômes arthritiques. Particulièrement, le traitement par le TFO diminue sensiblement l'inflammation synoviale et les lésions ostéocartilagineuses articulaires. Ces résultats sont les premiers à montrer la possibilité d'utiliser un TFO in vivo et offrent d'intéressantes perspectives thérapeutiquesTumor necrosis factor alpha (TNF-[alpha]), a pro-inflammatory cytokine, plays a key role in the pathogenesis of many inflammatory diseases, including arthritis. Neutralization of this cytokine by anti-TNF-[alpha] antibodies has shown its efficacy in rheumatoid arthritis and is now widely used. Nevertheless, some patients currently treated with anti-TNF-[alpha] remain refractory or become non-responder to these treatments. In this context, there is a need for new or complementary therapeutic strategies. Triplex forming oligonucleotides (TFO) can inhibit gene expression with high sequence-specificity by interacting with the DNA double-strand. In this study, we investigated if an anti-TNF-[alpha] TFO had a therapeutic activity on inflammatory processes in vitro and in vivo, as judged from effects on two rat arthritis models. This TFO interacted with the TNF-[alpha] gene promoter, and its inhibitory activity was verified and compared to that of siRNA in vitro. A local intra-articular preventive injection of TFO in both acute and chronic arthritis models significantly reduced the development of the disease. Furthermore, the TFO efficiently blocked synovitis and cartilage and bone destruction in the joints. The results presented here provide the first evidence that gene targeting by anti-TNF-[alpha] TFO modulates arthritis in vivo, thus providing proof of concept that it could be used as therapeutic tool for TNF-[alpha]-dependent chronic inflammatory disorders
3
Alazemi, Abdulrahman. "Investigation of Factors in Triplet-Triplet Annihilation Upconversion." University of Cincinnati / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1521189118425574.
Повний текст джерела
4
Westbrook, Emily Grace. "Development and Investigation of Methods for Improving Triplet-Triplet Annihilation Upconversion." University of Cincinnati / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1583154398097115.
Повний текст джерела
5
Kristoffersson, Fredrik. "Novel target genes of ZEB1 and Snail1 in triple-negative human breast cancer." Thesis, Uppsala universitet, Institutionen för medicinsk biokemi och mikrobiologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-356578.
Повний текст джерелаАнотація:
Breast cancer is comprised of several subtypes that are different from one another and thedivergence leads to different outcomes of the disease. There are known prognostic factors andphenotypic distinction in different biological factors and expression patterns, such as theestrogen receptor (ER), progesterone receptor (PR), Ki67, HER2/neu expression (HER2). Ingeneral, there are three breast cancer subtypes with the most recurring subtype being luminalA, and the other two being luminal B and triple negative breast cancer. Triple negative breastcancer is a heterogeneous subtype which is defined by the lack of expression of ERα, PR andHER2. Triple negative breast cancers are also very aggressive and have the worst prognosiscompared to the other two ERα positive tumors. The luminal A subtype can develop into ametastatic cancer thanks to the so-called epithelial-mesenchymal transition (EMT), whichaffects a subpopulation of epithelial cancer cells. EMT is the name of a process that takesplace during the embryonic development, the wound healing and cancer metastasis, where theepithelial cells will transform into mesenchymal cells which have higher invasive andmigratory properties. EMT occurs when epithelial cells lose their apical-basal polarity andthen the adherens- and tight junctions are dissolved. The adherens junction dissolution can beobserved as a downregulation of CDH1 (E-cadherin), which is regularly measured in EMTstudies. Many signaling pathways are associated with the promotion and establishment ofEMT e.g. transforming growth factor β (TGFβ), Notch and Wnt signaling. Bioinformaticscreening was performed to look for mRNA expression levels of ZEB1 and Snail1 indifferent breast cancer cell lines. By using chromatin immunoprecipitation-sequencing (ChIPSeq)in the triple negative (ER-, PR- HER2-) Hs578T breast cancer cell line, a genome-widescreen for ZEB1 and Snail1 binding sites had been performed before the start of the project.The Hs578T cell line expresses many of the EMT transcription factors that are relevant forthe project. Since the signaling of TGFβ is crucial for these genes, manipulation of thissignaling pathway is needed to be able to analyse its importance for the function of thesegenes. To inhibit the activity of TGFβ, the small molecule GW6604 was used to inhibit theTGFβ type I receptor kinase (TβRI) and in that way inhibiting the signaling from thisreceptor. In addition, ZEB1 and Snail1 were knocked out by the use of the transfection andCRISPR/Cas9 knockout technique. By investigating mRNA and protein levels of chosengenes in both control Hs578T cells and ZEB1 and Snail1 knockout Hs578T cells, up or downregulation of some of these genes can be seen with stimulation with TGFβ. The knockout ofSnail1 but not of ZEB1 indicated that the loss of Snail1 generated breast cancer cells thatcould try to revert to epithelial at the phenotypic level.
6
Kim, Hyun-Min. "Genome instability induced by triplex forming mirror repeats in S.cerevisiae." Diss., Georgia Institute of Technology, 2009. http://hdl.handle.net/1853/33874.
Повний текст джерелаАнотація:
The main goal of this research is to understand molecular mechanisms of GAA/TTC-associated genetic instability in a model eukaryotic organism, S. cerevisiae. We demonstrate that expanded GAA/TTC repeats represent a threat to eukaryotic genome integrity by triggering double-strand breaks and gross chromosomal rearrangements. The fragility potential strongly depends on the length of the tracts and orientation of the repeats relative to the replication origin and to block replication fork progression. MutSbeta complex and endonuclease activity of MutLalpha play an important role in facilitation of fragility. In addition to GAA/TTC triplex forming repeats, non-GAA polypurine polypyrimidine mirror repeats that are prone to the formation of similar structures were found to be hotspots for rearrangements in humans and other model organisms. These include H-DNA forming sequences located in the major breakpoint cluster region at BCL2, intron 21 of PKD1, and promoter region of C-MYC. Lastly, we have investigated the effect of the triplex-binding small molecules, azacyanines, on GAA-mediated fragility using the chromosomal arm loss assay. We have found that in vivo, azacyanines stimulate (GAA/TTC)-mediated arm loss in a dose dependent manner in actively dividing cells. Azacyanines treatment enhances the GAA-induced replication arrest. We discovered that also, azacyanines at concentrations that induce fragility also inhibit cell growth. Over 60% of yeast cells are arrested at G2/M stage of the cell cycle. This implies an activation of DNA-damage checkpoint response.
7
Barona, Marco Antonio Acevedo. "Epistasia e interação epistasia por locais para a produção de grãos em soja." Universidade de São Paulo, 2007. http://www.teses.usp.br/teses/disponiveis/11/11137/tde-20032008-173225/.
Повний текст джерелаАнотація:
Nos programas de melhoramentos de soja as progênies endogâmicas são frequentemente avaliadas como possíveis cultivares. O estudo da estrutura da variação genética entre progênies de diferentes gerações de autofecundação depende da ação dos locos envolvidos e da variação do caráter sob estudo. Em soja o caráter produção de grãos (PG) é considerado o de maior importância econômica e destaca-se por apresentar herança quantitativa e ser altamente influenciada pelo ambiente. As estratégias de seleção utilizadas para o desenvolvimento de cultivares em soja poderiam ser otimizadas através do estudo da importância relativa dos componentes de variância, particularmente a proporção de variação devida à interação não alélica (epistasia). Com o objetivo de estudar a variação epistática e sua interação com ambientes (locais) para a produção de grãos em soja utilizou-se o delineamento "Triple Test Cross Modificado" (TTC) de JINKS, PERKINS e BREESE (1969). Uma amostra de 32 linhagens (Pi) derivadas de um cruzamento biparental foi cruzada com duas linhagens divergentes (L1 e L2) contrastantes para PG, derivadas da mesma população (testadores). Os experimentos de avaliação foram conduzidos no ano agrícola de 2006/2007 em dois locais (Piraciacaba e Anhembi) em delineamentos em látice triplo 10 x 10. Os tratamentos correspondiam aos 32 cruzamentos Pi x L1, 32 cruzamentos Pi x L2, 34 linhas puras (32 Pi + 2 testadores) e duas testemunhas comerciais. De acordo com a metodologia utilizada foram estudados os contrastes ( i 2i 1i P L L - + ) para avaliar a ocorrência de epistasia. Os resultados das análises individuais mostraram que a epistasia afetou a expressão da produção de grãos em ambos os locais. A análise conjunta permitiu detectar significância para locais, epistasia e interação epistasia por locais, indicando que a produção de grãos em soja é afetada pela interação não alélica (epistasia) e que esta não é consistente entre locais. O estudo do contraste ( i 2i 1i P L L - + ) das médias individuais nas análises por local e na análise conjunta indicou haver contribuição diferencial dos genótipos para a epistasia. Os resultados gerais indicam que a epistasia pode ser um componente importante para a expressão da produção de grãos de soja e, consequentemente, esta deveria ser incluída nos modelos para a decomposição dos componentes da variância genética.In soybean breeding programs the selfing progenies are generally evaluated as possible cultivars. The study of the structure of the genetic variation among progenies in different generations of selfing depends upon the action of the loci involved and the variability of the trait under study. In soybeans, grain yield is the most important trait and it is characterized by a quantitative inheritance and highly influenced by the environment. The selection strategies used for the development of soybean cultivars could be optimized through the study of the relative importance of the variance components, in particular the proportion of the non-allelic interaction component (epistasis). In order to study the epistatic variation and its interaction with locations for grain yield in soybeans the "Modified Triple Test Cross" (TTC) method (JINKS, PERKINS e BREESE, 1969) was used. A sample of 32 inbred lines (Pi) derived from a single cross were crossed with two divergent inbred lines (L1 e L2) of the same population (testers). The experiments were carried out in the 2006/2007 growing season in two locations (Piracicaba and Anhembi) in a 10x10 triple lattice design. Entries consisted of the 32 Pi x L1 crosses, 32 Pi x L2 crosses, 34 lines (Pi + 2 testers) and 2 commercial checks. Following the methodology, the contrasts ( i 2i 1i P L L - + ) were studied in order to evaluate the occurrence of epistasis. General results showed that epistasis affected grain yield in soybeans in both locations. Significance for locations, epistasis and epistais by locations interactions were also detected in the joint analysis of variance, indicating that grain yield in soybeans is affected by the non-allelic interaction (epistasis) and that the epistasis is not consistent in different locations. A study of the contrast ( i 2i 1i P L L - + ) of individual means for each location and in the joint analyses indicated the occurrence of differential contribution of the genotypes for the epistasis. General results had demonstrated that epistasis could be an important component for the expression of grain yield in soybeans and consequently it should be included in the model for the partition of the genetic components of variance.
8
Cherta, Cucala Laura. "Potencial de diferentes analizadores y fuentes de ionización en cromatografía de gases-espectrometría de masas en el campo de la seguridad alimentaria y medioambiental." Doctoral thesis, Universitat Jaume I, 2014. http://hdl.handle.net/10803/285680.
Повний текст джерелаАнотація:
En la presente Tesis Doctoral se han estudiado las posibilidades de la cromatografía de gases (GC) acoplada a espectrometría de masas (MS) con distintos analizadores y fuentes de ionización para la determinación de contaminantes en muestras alimentarias y medioambientales. La singularidad de los cuatro instrumentos diferentes empleados reside en los analizadores de masas que los componen: cuadrupolo simple (Q), tiempo de vuelo (TOF), triple cuadrupolo (QqQ) e híbrido cuadrupolo tiempo de vuelo (QTOF). En los dos primeros sistemas, el modo de ionización aplicado ha sido el más frecuentemente utilizado en GC, la ionización electrónica (EI), mientras que en los dos últimos se ha hecho uso de la ionización a presión atmosférica (APCI), cuyo acoplamiento con la cromatografía de gases es relativamente reciente. El potencial de estas técnicas se ha investigado tanto para el análisis target como para non-target.
9
"Characterization of the optical properties of metalloporphyrins in TiO2 sol-gel films for photon upconversion applications." Thesis, 2013. http://hdl.handle.net/10388/ETD-2013-10-1028.
Повний текст джерелаАнотація:
The photophysical properties of a series of Zn (II) porphyrins adsorbed onto a
semiconductor were investigated using steady-state absorbance and emission
measurements. The ability of the porphyrins to undergo triplet-triplet annihilation (TTA), a photophysical process through which photons in the red and near-infrared (NIR) regions of the optical spectrum can be converted into higher energy photons (upconversion), was explored. Aggregation capabilities were determined to verify possibility of these molecules to undergo triplet-triplet annihilation (TTA). TTA has significant potential for increasing the efficiency of dye-sensitized solar cells (DSSCs) by
upconverting photons in the energy rich NIR region of the solar spectrum. A key
requirement for efficient TTA is aggregation of the sensitizer dye, and in this thesis, we have examined the aggregation of porphyrins in TiO2-based sol-gel films. Solution phase absorption and emission studies were conducted using zinc (II) tetraphenylporphyrin and
three of its functionalized derivatives, tetra(4-aminophenyl)porphyrin Zn(II), tetra(4-carboxyphenyl)porphyrin Zn(II), and tetra(4-sulfonatophenyl)porphyrin Zn(II), to
evaluate their potential as DSSC sensitizers on TiO2 thin films. Mesoporous TiO2 thin films were synthesized, using a polymer-templating sol-gel route, and characterized with
tunneling electron microscopy (TEM), atomic force microscopy (AFM), and UV-Vis absorbance measurements. Spectroscopy measurements were also carried out on porphyrin-sensitized TiO2 thin films and compared to solution-based results. A simple DSSC was constructed and used to further explore the application of zinc (II) porphyrin sensitizers in photovoltaic applications.
10
Figueiredo, Sónia Filipa da Silva. "The importance of document management and the future of clinical trials archive." Master's thesis, 2018. http://hdl.handle.net/10316/84486.
Повний текст джерелаАнотація:
Dissertação de Mestrado em Biotecnologia Farmacêutica apresentada à Faculdade de FarmáciaO ensaio clínico é uma parte fundamental no desenvolvimento de um novo medicamento, fazendo a ponte entre a investigação científica e a clínica e, posteriormente, o mercado. A parte clínica de um ensaio tem uma duração restrita, cedendo o lugar aos documentos do arquivo, a fim de “contarem a história do ensaio”. São esses documentos que suportam o pedido de submissão às autoridades para introdução no mercado do produto teste; e estão disponíveis no momento de uma inspecção por parte das autoridades competentes. Com esta dissertação pretende-se fazer uma revisão acerca do arquivo de ensaios clínicos. A recolha de dados de forma eletrónica e a aplicação das novas tecnologias ao arquivo dará origem a novas formas de Trial Master Files. Para tal é importante uma análise das vantagens e desvantagens do arquivo físico, em papel, versus as mais recentes tecnologias, atualmente, presentes no mercado. A escala, a complexidade e o custo dos ensaios clínicos está a aumentar e a evolução da tecnologia a que hoje assistimos, acompanhado da gestão da documentação do ensaio clínico oferecem novas oportunidades para aumentar a eficiência e reduzir o custo.Um ensaio clínico, para além de contribuir para a inovação da medicina e da ciência, continua a ser uma atividade empreendedora com necessidade de ir acompanhando o crescimento e a modernização que acontece em seu redor.
Clinical Trials are a key part of the development of a new drug, connecting scientific and clinical research and, later, the market. The clinical part of the trial has a restricted duration, giving place to the documents in the file, to "tell the history of the trial". These documents support the submission to the authorities for the introduction of the test product on the market; and are available at the time of inspection by the competent authorities. With this dissertation we intend to review the archive of clinical trials. The collection of data on paper or electronically and the application of new technologies to the archive, which will originate new forms of Trial Master Files. For this, it is important to analyze the advantages and disadvantages of the physical archive, in paper, versus the most recent technologies currently present in the market. The scale, complexity, and cost of clinical trials are increasing, and the evolution of the technology we see today, coupled with the management of clinical trial documentation, offers new opportunities to increase efficiency and reduce costs. A clinical trial, in addition to contributing to the innovation of medicine and science, remains an entrepreneurial activity with the need to keep up with the growth and modernization that takes place around it.
Книги з теми "TTF triple"
1
Boyd, Tristan, and Arthur Kavanaugh. Biologic DMARDs (TNF inhibitors). Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198737582.003.0029.
Повний текст джерелаАнотація:
Tumor necrosis factor-α inhibitors (TNFi) can effectively treat all domains of disease in patients with psoriatic arthritis (PsA). They have been shown to be effective and also generally safe and well tolerated in numerous clinical trials. This chapter reviews clinical trial evidence for the efficacy and safety of TNFi in PsA and highlights evidence-based treatment recommendations for their use. Emerging treatment strategies involving the use of TNFi in the management of PsA are also discussed.
2
Rivera-Lara, Lucia, and Romergryko G. Geocadin. Neurobiology of Brain Injury after Cardiac Arrest. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0189.
Повний текст джерелаАнотація:
The publication of two sentinel, multicenter, randomized controlled trials in The New England Journal of Medicine in 2002 provided evidence for the beneficial use of therapeutic hypothermia (TTH) to 32° to 34°C in resuscitated patients after cardiac arrest with a shockable rhythm. The number needed to treat to provide a favorable neurological outcome was 6, and TTH is a recommended treatment in the American Heart Association (AHA) Resuscitation Guidelines. This chapter describes the biological basis of disorders of arousal and awareness after cardiac arrest, the mechanisms of ischemic cell death, and the biological bases of the some therapeutic interventions.
3
Ray, Sumantra (Shumone), Sue Fitzpatrick, Rajna Golubic, Susan Fisher, and Sarah Gibbings, eds. Essential documents. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199608478.003.0022.
Повний текст джерелаАнотація:
It is a legal requirement for sponsors and investigators to maintain essential documentation. This chapter outlines the ICH GCP E6 requirements for documentation before, during and after the study. It describes each document and its purpose in the study. The chapter also describes how to deal with additional documentation kept by sponsors and sites but not addressed in the guidelines e.g. correspondence, emails and notes to file, The organisation of the trial master file (TMF) is not defined in guidelines but many companies and institutions will have a filing system described in SOPs, most are numeric and an example content list is given. The TMF must be maintained and stored correctly and version control of documentation is vital to maintain the audit trail. The legislation does not distinguish between commercial and non-commercial/academic studies but researchers are expected to adhere to the principles of GCP and maintain the TMF requirements. Originally TMF were paper based but the eTMF is now widely used by commercial sponsors. The retention time for the TMF has changed on a number of occasions the EU Regulation clearly states that essential documentation must be kept for 25 years and must be readily available for inspection.
4
Cañete, Juan D., and Julio Ramírez. Enthesitis. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198737582.003.0011.
Повний текст джерелаАнотація:
Enthesitis is common in psoriatic arthritis (PsA) occurring in50–60% of patients in clinical trials. Outcome measures for enthesitis have been developed, but its clinical diagnosis may be challenging at sites other than the Achilles and plantar insertions. Power Doppler ultrasound is more sensitive than clinical examination in detecting inflammatory and/or structural changes in asymptomatic patients, which have an unknown significance. Magnetic resonance imaging is useful to evaluate enthesitis and the best technique for osteitis. The concept of synovial–entheseal complex highlights the functional link between the entheseal site and synovium, supporting an important role for biomechanical stress in enthesitis, which is proposed as the primary lesion in PsA. Animal models have improved our understanding of molecular pathways, particularly TNF and IL-23/IL-17 cytokines, and new successful targeted therapies have been developed to treat enthesitis. Prospective studies integrating clinical and image examination will be crucial to better define the clinical implications of enthesitis changes.
5
Sternbach, Marion. Apheresis in the ICU. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0268.
Повний текст джерелаАнотація:
This chapter describes therapeutic plasma exchange, as well as cytapheresis for hyperleukocytosis and essential thrombocythemia, as well as harvesting haematological stem cells (HSC) for transplantation. Instrumentation and techniques are mostly density centrifugation, much less column adsorption for antibodies or membrane filtration for noxious molecules. Pathophysiology of apheresis is dealt with in great detail with emphasis on prevention and treatment of side effects, much more critical in the intensive care unit (ICU) setting. Main manifestations are: hypocalcaemia due to chelation by anticoagulants, hypo- and less hypervolaemia, allergic reactions to sedimenting and volume replacement starches or plasma, depletion of coagulation factors, vitamin K, immunoglobulins, lymphocytes with long lifespan and platelets. Wash-out of drugs for comorbid or underlying conditions occurs inadvertently. Main indications for plasma exchange are thrombotic thrombocytopenic purpura (TTP)/haemolytic uraemic syndrome (HUS) with plasma or cryo-poor supernatant (based on RCT), hyperviscosity syndromes, post-transfusion purpura (PTP) and auto-immune haemolytic anaemia (AIHA), where all other treatments have failed. In cold agglutinin disease, cryoglobulinaemia, coagulation factor inhibitors and ABO incompatible HSC transplants, plasmapheresis has proven useful. Myeloma with renal failure does not seem to benefit significantly from plasma exchange (randomized controlled trials proven).
6
Fleischmann, Roy. Signalling pathway inhibitors. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081.
Повний текст джерелаАнотація:
Oral, small-molecule signalling pathway inhibitors, including ones that inhibit the JAK and SyK pathways, are currently in development for the treatment of rheumatoid arthritis (RA). Tofacitinib is an orally administered small-molecule inhibitor that targets the intracellular Janus kinase 3 and 1 (JAK1/3) molecules to a greater extent than JAK2 while baricitinib (formerly INCB028050) predominantly inhibits JAK1/2. Many of the proinflammatory cytokines implicated in the pathogenesis of RA utilize cell signalling that involves the JAK-STAT pathways and therefore inhibition of JAK-STAT signalling, by targeting multiple RA-associated cytokine pathways, has the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key immune cells. Fostamatinib disodium is an orally available inhibitor of spleen tyrosine kinase (SyK), which is a cytoplasmic tyrosine kinase that is an important mediator of immunoreceptor signalling in mast cells, macrophages, neutrophils, and B cells. Interruption of SyK signalling may interrupt production of tumour necrosis factor (TNF) and metalloproteinase and therefore affect RA disease activity. Tofacitinib has been investigated in multiple phase 2 and phase 3 trials which have investigated its efficacy (clinical, functional, and radiographic) and safety in patients who have failed disease-modifying anti-inflammatory drugs (DMARDs) as monotherapy or in combination with DMARDs, compared to an inhibitor of tumour necrosis factor alpha (TNFα) and in patients who have failed TNFα inhibitors. The efficacy of fostamatinib and baricitinib has been investigated in phase 2 trials; both are in large phase 3 clinical programmes. Each of these medications has demonstrated efficacy; their safety profile has been shown to be different from each other and from currently approved biological agents. This chapter discusses what is currently known and understood about their efficacy and safety.
Частини книг з теми "TTF triple"
1
Hamel, J. "Planovalguskorrektur durch tarsale Triple-Osteotomie (TTO)." In Sprunggelenk und Rückfuß, 163–71. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-45571-5_17.
Повний текст джерела
2
Vermorken, Jan B. "Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer." In Critical Issues in Head and Neck Oncology, 155–79. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_11.
Повний текст джерелаАнотація:
AbstractThe treatment of locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) is reviewed, highlighting the milestones in systemic therapy in that setting, with focus on the role of induction chemotherapy (ICT). The road to what is now considered the standard ICT regimen, i.e. the TPF (docetaxel/cisplatin/5-FU) regimen is described, and the differences between the European and the American TPF are discussed. The article describes the respective roles of ICT for larynx preservation, for treatment intensification, its role in patients with borderline resectable or unresectable oral cavity cancer, its role as a selection tool for radiotherapy dose de-escalation in patients with oropharyngeal squamous cell cancer (OPSCC) and its potential future role in strategies aiming at synchronous oligometastatic disease.ICT has an established role for organ preservation in advanced laryngeal and hypopharyngeal cancer and the TPF regimen has been validated in that setting. This approach is presently being compared in a randomized controlled trial to concurrent chemoradiotherapy (CCRT), which in many parts of the world is considered the standard organ preservation procedure. There remains uncertainty about the benefit of the sequential approach of ICT followed by CCRT, despite the fact that ICT significantly reduces the occurrence of distant metastases. It is advised that future studies should include patients who have the highest risk to develop distant metastases, in particular patients with low neck nodes and matted nodes. Moreover, further studies in patients with HPV-associated OPSCC at risk for distant failure (T4 or N3 disease) should be considered for that also. These approaches still need to be confirmed in adequately sized randomized controlled trials. Outside clinical trials, the utility of ICT is restricted to uniquely pragmatic clinical scenarios, such as unavoidable delay in radiation or in the situation that RT is not tolerated or feasible. This can happen when there is severe pain from advanced disease or there is impending airway compromise or neurologic dysfunction that necessitates rapid initiation of treatment. In all those circumstances whether within the context of trials or outside trials, it is imperative that the present backbone of ICT, the TPF regimen, is being administered by experienced oncologists, familiar with the necessary protocols and supportive care requirements to ensure patient safety and maximize adherence throughout the treatment.Future areas of research are the role of ICT in strategies whereby ICT is combined with upfront metastases-directed treatments and the usefulness of targeted agents or immune checkpoint inhibitors in the induction setting. Studies in that direction have already started. Finally, the application of radiographic, proteomic and genomic biomarkers will get attention to further define prognostic groups and guide treatment selection with greater precision.
3
D’Anna, C., D. Bibbo, M. Goffredo, M. Schmid, and S. Conforto. "Efficacy of TtB-Based Visual Biofeedback in Upright Stance Trials." In IFMBE Proceedings, 1755–58. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-00846-2_433.
Повний текст джерела
4
Niu, Xiaoshuang, and Yungan Tao. "New Developments in the Management of Nasopharyngeal Carcinoma." In Critical Issues in Head and Neck Oncology, 327–35. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_22.
Повний текст джерелаАнотація:
AbstractNasopharyngeal carcinomas (NPC) have unique characteristics with a specific geographic distribution and radiotherapy (RT) is the cornerstone of initial treatment due to its radiosensitive behaviour and deep-seated location. Intensity modulated radiotherapy (IMRT) has become the standard RT technique compared with 2D/3D and could reduce the late toxicities such as xerostomia. We established the international guideline for the delineation of clinical target volumes (CTV) and dose prioritization and constraint guideline for a better implementation of IMRT for NPC. The role of RT in addition to systemic therapy for the initially diagnosed metastatic NPC has recently been investigated in a randomized trial. The meta-analysis MAC-NPC confirmed the role of chemotherapy in addition to RT for NPC and established concomitant chemoradiotherapy (CCRT) as a standard of care in locally advanced (LA) NPC. In the recent actualization of MAC-NPC and network meta-analysis, more chemotherapy (adjuvant or induction) has been suggested to further improve treatment efficacy. However, a randomized trial did not shown survival benefit of adjuvant chemotherapy in addition to CCRT in LA-NPC. More recently, several phase III trials (French GORTEC trial and Chinese trials) showed benefit of induction chemotherapy (PF/TPF/GP) when added to cisplatin-based chemoradiotherapy. Preliminary study has failed to show benefit of adjuvant chemotherapy for the patients with detectable plasma Epstein Barr virus (EBV) DNA after chemoradiotherapy. The presentation will also focus on the ongoing trials with association of immune checkpoint inhibitors with chemoradiotherapy and the role of EBV DNA during or after treatment among others.
5
Bentz, B. L., and R. E. Honig. "Design of an Organic SIMS Instrument with Separate Triple Stage Quadrupole (TSQ) and Time-of-Flight (TOF) Spectrometers." In Springer Proceedings in Physics, 192–97. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-82718-1_36.
Повний текст джерела
6
Deng, Shuang, David Scott, and Uttam Garg. "Quantification of Five Clinically Important Amino Acids by HPLC-Triple TOF™ 5600 Based on Pre-column Double Derivatization Method." In Clinical Applications of Mass Spectrometry in Biomolecular Analysis, 47–53. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3182-8_6.
Повний текст джерела
7
Sande, Beverly, and Camille S. Burnett. "The Triage Implementation Framework." In Collaborative Models and Frameworks for Inclusive Educator Preparation Programs, 14–31. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-6684-3443-7.ch002.
Повний текст джерелаАнотація:
There are several models and frameworks used for continuous improvement in many education preparation programs (EPPs). Each program selects a framework or model that would best meet their improvement needs. In this chapter, the authors propose a novel framework that EPPs can use to prioritize continuous improvement activities. This model serves as a pre-implementation framework that can assist a team in determining how to select a critical area of implementation with the greatest impact. The novel framework is the triage implementation framework (TIF). The authors will describe a case study that used TIF, what it means to triage, and how the TIF can benefit EPPs.
8
Templin, Christian. "Introduction." In ESC CardioMed, 1277–78. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0313.
Повний текст джерелаАнотація:
Takotsubo syndrome (TTS) has been recognized for over 25 years; however, its pathophysiology is still unclear. Although this disease is increasingly recognized, the true prevalence of TTS is still underestimated and the disease course underappreciated. Extensive research over the last years has contributed to a better understanding of TTS. As such, TTS is no longer only the disease of postmenopausal women with an emotional stressor, apical ballooning, and benign prognosis. TTS has a much more diverse clinical picture and can result in acute life-threating complications. Therapeutic management of TTS is still challenging and evidence-based treatment entirely lacking. Therefore, prospective trials are needed to assess different treatment options in order to improve the outcome of TTS patients.
9
Rosales, Jesus. "Drive large TFT-LCD displays with a space-saving triple-output regulator." In Analog Circuit Design, 625–26. Elsevier, 2015. http://dx.doi.org/10.1016/b978-0-12-800001-4.00291-x.
Повний текст джерела
10
Ahmed, Nazmin. "Management of High-Grade Meningioma: Present, Past and Promising Future." In Central Nervous System Tumors [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.108414.
Повний текст джерелаАнотація:
High-grade meningiomas have a persistent therapeutic challenge, which the World Health Organization (WHO) categorizes as grade II and III lesions, represent 10–20% and 5% of individuals with meningiomas, respectively. Although grade I meningiomas can be completely surgically removed and have long-term progression-free survival, higher grade meningiomas are more likely to return aggressively and to be resistant to conventional treatments. Recently, stereotactic radiosurgery (SRS) has offered promise for the treatment of localized tumors. The era of molecular targeted treatment is now upon us. Patients are being enrolled in clinical trials with a variety of innovative medications that target driver mutations, and these trials might result in more effective treatment plans. Alpha-interferon, vascular endothelial growth factor inhibitors, and somatostatin receptor agonists are among the medications that are advised for the medical treatment of meningiomas in addition to radiation and surgical excision. For the treatment of meningioma, efforts to find novel informative mutations and protein biomarkers have advanced. Several patient populations have shown promise for improved outcomes with EZH2 inhibition. Overall, it is hoped that targeted research and the application of those strategies, such as PRRT and TTF devices, would lead to better results in future. This chapter aims to discuss the neuroimaging features of high grade meningiomas, diagnostic and therapeutic implications of recently discovered genetic alterations and outcome. There will be a brief review focusing on ongoing clinical trials of novel therapeutic agents and future research scope in this arena.
Тези доповідей конференцій з теми "TTF triple"
1
Wu, Jinyuan, M. Wang, E. Gottschalk, and Z. Shi. "Curved Track Segment Finding Using Tiny Triplet Finder (TTF)." In 2006 IEEE Nuclear Science Symposium Conference Record. IEEE, 2006. http://dx.doi.org/10.1109/nssmic.2006.356077.
Повний текст джерела
2
Jinyuan Wu, M. Wang, E. Gottschalk, and Z. Shi. "The application of tiny triplet finder (TTF) in BTeV pixel trigger." In 14th IEEE-NPSS Real Time Conference, 2005. IEEE, 2005. http://dx.doi.org/10.1109/rtc.2005.1547448.
Повний текст джерела
3
Lee, Jongchan, Jaehyun Moon, Jae-Eun Pi, Sung Haeng Cho, Hee-Ok Kim, Himchan Oh, Chi-Sun Hwang, Seong-Deok Ahn, Seung-Youl Kang, and Kwang-Ho Kwon. "Transparent triple-layer oxide TFT for enhanced photo switching characteristics." In 2018 25th International Workshop on Active-Matrix Flatpanel Displays and Devices (AM-FPD). IEEE, 2018. http://dx.doi.org/10.23919/am-fpd.2018.8437364.
Повний текст джерела
4
Chandler, Benjamin C., Leah Moubadder, Cassie Ritter, Yashar Niknafs, Eric Olsen, Meleah Cameron, Meilan Liu, et al. "Abstract 677: TTK: A novel target for radiosensitization in triple-negative breast cancers." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-677.
Повний текст джерела
5
Ghosh, Angshuman, Karan Deshmukh, and Gracious Ngaile. "Database for Real-Time Loading Path Prediction for Tube Hydroforming Using Multidimensional Cubic Spline Interpolation." In ASME 2010 International Manufacturing Science and Engineering Conference. ASMEDC, 2010. http://dx.doi.org/10.1115/msec2010-34099.
Повний текст джерелаАнотація:
Tube Hydroforming (THF) is a metal-forming process that uses a pressurized fluid in place of a hard tool to plastically deform a given tube into a desired shape. In addition to the internal pressure, the tube material is fed axially toward the die cavity. This process has various applications in the automotive, aerospace, and bicycle industries. Accurate coordination of the fluid pressure and axial feed, collectively referred to as a loading path, is critical to THF. Workable loading paths are currently determined by trial and error, which can be time consuming. This paper discusses an innovative technique for developing an interactive, real-time database that would be able to predict loading paths for typical classes of THF products and hence, reduce the computational time required. By classifying most of the commercial THF parts into families, parameters such as material properties, part geometry, and tribological factors were simulated by category and stored in the database. Multidimensional cubic spline interpolation was implemented to enable an end user to request from the database a loading path for a wide range of conditions. Test results from the database for different THF families were shown to approximate the simulated results. In addition, by reducing the computation time, the use of interpolation techniques eliminates the need for carrying out multiple simulations for similar THF parts.
6
Saboori, M., J. Gholipour, H. Champliaud, A. Gakwaya, J. Savoie, and P. Wanjara. "Prediction of Burst Pressure in Multi Stage Tube Hydroforming of Aerospace Alloys." In ASME Turbo Expo 2015: Turbine Technical Conference and Exposition. American Society of Mechanical Engineers, 2015. http://dx.doi.org/10.1115/gt2015-43893.
Повний текст джерелаАнотація:
Bursting, an irreversible failure in tube hydroforming (THF), results mainly from the local plastic instabilities that occur when the biaxial stresses imparted during the process exceed the forming limit strains of the material. To predict the burst pressure, Oyane’s and Brozzo’s decoupled ductile fracture criteria were implemented as user material models in a dynamic nonlinear commercial 3D finite element (FE) software, Ls-Dyna. THF of a round to V-shape was selected as a generic representative of an aerospace component for the FE simulations and experimental trials. To validate the simulation results, THF experiments up to bursting were carried out using Inconel 718 (IN 718) tubes with a thickness of 0.9 mm to measure the internal pressures during the process. When comparing the experimental and simulation results, the burst pressure predicated based on Oyane’s decoupled damage criterion was found to agree better with the measured data for IN 718 than Brozzo’s fracture criterion.
7
Lee, Jeongmin. "Abstract 1041: TGF-β1-induced EMT is suppressed by berberine in triple negative breast cancers". У Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1041.
Повний текст джерела
8
Wang, Ling, Zhimin Hou, Emily Gronseth, Janet Rader, David Harder та Ramani Ramchandran. "Abstract LB-215: Astrocytes promote brain metastasis of triple-negative great cancer through TGF-β2/ANGPTL4 axis". У Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-lb-215.
Повний текст джерела
9
Ji, H., Z. Wang, C. Mo та M. Zhang. "Abstract P2-12-02: discovery of the β-catenin/Tcf inhibitors for treatment of triple negative breast cancer". У Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p2-12-02.
Повний текст джерела
10
Calvo, Veronica, Orsi Giricz, and Paraic A. Kenny. "Abstract A54: TACE-regulated TGF-alpha shedding drives GRB7-dependent invasion in triple-negative breast cancer cell lines." In Abstracts: AACR Special Conference on Tumor Invasion and Metastasis - January 20-23, 2013; San Diego, CA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.tim2013-a54.
Повний текст джерелаЗвіти організацій з теми "TTF triple"
1
Zhao, Binghao, Yu Wang, and Wenbin Ma. Comparative Efficacy and Safety of Therapeutics for Elderly Glioblastoma: a Bayesian Network Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0094.
Повний текст джерелаАнотація:
Review question / Objective: At this time, a comprehensive systematic review and network meta-analysis (NMA) was conducted to: (1) fill the research gap by giving rankings on treatment efficacy; (2) provide statistical evidence of not head-to-head comparisons; (3) seek out the best and up-to-date therapeutic strategy reported in latest RCTs; (4) address potential adverse events (AEs) of available treatments. Condition being studied: The incidence of glioblastoma (GBM) increases with age, until now, there has been less evidence on the optimal treatments for elderly GBM since only general GBM populations were included in clinical trials. Given the poor survival of elderly GBM, we collected randomized controlled trials about newly diagnosed GBM (ndGBM) and recurrent GBM, and conducted a Bayesian network meta-analysis on ndGBM regarding overall survival (OS) and progression-free survival (PFS). We revealed TTF + TMZ and TMZ + HFRT were likely to be best treatments for OS; BEV + HFRT and TMZ + HFRT were likely to be best options for PFS. Current study is the most comprehensive and powered network analysis on elderly GBM until now, it also provides more insights for elderly GBM management.
2
Tian, Cong, Jianlong Shu, Wenhui Shao, Zhengxin Zhou, Huayang Guo та Jingang Wang. The efficacy and safety of IL Inhibitors, TNF-α Inhibitors, and JAK Inhibitor on ankylosing spondylitis: A Bayesian network meta-analysis of a “randomized, double-blind, placebo-controlled” trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, вересень 2022. http://dx.doi.org/10.37766/inplasy2022.9.0117.
Повний текст джерелаАнотація:
Review question / Objective: In this study, we conducted a Bayesian network meta-analysis to evaluate the efficacy and safety of interleukin (IL) inhibitors, tumor necrosis factor-alpha (TNF-α) inhibitors, and Janus kinase (JAK) inhibitors on ankylosing spondylitis (AS).The purpose of this study is to compare the effectiveness and safety of different interventions for treating AS to provide insights into the decision-making in clinicalpractice. Condition being studied: Ankylosing spondylitis. Based on the Bayesian hierarchical model, we conducted a network meta-analysis using the gemtc package in R software (version 4.1.3) and Stata software (version 15.1). Cong Tian and Jianlong Shu contributed to the conception and design of the study and supervised the tweet classification. All authors drafted the manuscript. Wenhui Shao, Zhengxin Zhou, Huayang Guo and Jingang Wang contributed to data management and tweet classification. Cong Tian, Jianlong Shu and Zhengxin Zhou performed the statistical analysis. Cong Tian, Jianlong Shu, Wenhui Shao and Zhengxin Zhou reviewed the manuscript.
3
Blanken, Annelies, Bafrin Abdulmajid, Eva van Geel, Joost Daams, Martin van der Esch, and Michael Nurmohamed. Effect of tumor necrosis factor inhibiting treatment on arterial stiffness and arterial wall thickness in rheumatoid arthritis patients: protocol for a systematic review and planned meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0131.
Повний текст джерелаАнотація:
Review question / Objective: The aim of this systematic review is to evaluate the effect of TNF inhibiting treatment on arterial stiffness (as measured with pulse wave velocity and augmentation index) and arterial wall thickness (as measured with carotid intima media thickness) in rheumatoid arthritis patients. Condition being studied: Rheumatoid arthritis is a chronic autoimmune disorder, which affects approximately 1% of the population worldwide. Information sources: The following electronic databases will be searched for potentially eligible studies: EMBASE, MEDLINE, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform. For the studies identified as eligible for inclusion, similarity tracking will be used to identify more potentially relevant articles with the ‘related article’ feature in PubMed. In addition, a citation search will be performed for included studies to identify articles that have cited them. Reference lists of the included studies and previous reviews on the subject will be searched for potentially relevant studies. ResearchGate profiles of top authors on the subject will be investigated to identify potentially relevant data points. For ongoing or finished studies that are potentially eligible, but without a publication, study authors will be contacted for information. When additional information is needed, study authors will be contacted as well.